PTD-DBM

Overview

PTD-DBM (Protein Transduction Domain–Dvl-Binding Motif) is described by vendor and educational guides as a synthetic research peptide designed to block the CXXC5–Dishevelled (Dvl) interaction and disinhibit Wnt/beta-catenin signaling in hair follicles^3,7. One peptide profile explains that "PTD" refers to the protein transduction domain, which enables cellular entry across the stratum corneum, while "DBM" refers to the Dishevelled-binding motif that physically competes with CXXC5 for the Dvl PDZ domain(vendor claim).

Origin

Several sources report that PTD-DBM was developed by Professor Kang-Yell Choi's laboratory at Yonsei University in South Korea, with CXXC5 identified as a negative-feedback regulator of the Wnt/beta-catenin pathway by Kim and colleagues in 2015. One profile describes it as a 25-amino-acid peptide containing an eight-arginine PTD sequence (RRRRRRRR) fused to a DBM segment (RKTGHQICKFRK), with CAS number 1609454-11-6, and one vendor guide gives a molecular weight of approximately 2,500 Da⁷. These molecular figures each come from a single low-tier vendor page.

Rationale

Educational sources note that Wnt/beta-catenin signaling is the dominant molecular pathway governing hair follicle development, regeneration, and cycling, and that inactivation of beta-catenin causes dramatically reduced proliferation of hair progenitor cells and premature entry into catagen(vendor claim). A 2007 Nature paper by Ito, Cotsarelis, and colleagues demonstrated that Wnt signaling can produce entirely new follicles in adult mouse skin after wounding. Vendor material describes that in androgenetic alopecia the DHT→PGD2→CXXC5 axis upregulates CXXC5, suppressing Wnt signaling and arresting follicle cycling, and that PTD-DBM is proposed to reverse this by restoring Dvl-mediated signaling(vendor claim).

Preclinical evidence

A 2015 study (PubMed 26056233) reported that CXXC5 serves as a negative-feedback regulator of Wnt/beta-catenin by binding Dvl, that CXXC5 protein levels were reduced in human acute-wound keratinocytes and fibroblasts, that CXXC5(-/-) mice showed accelerated cutaneous wound healing with enhanced keratin 14 and collagen synthesis, and that PTD-DBM disrupted the CXXC5-Dvl loop and activated beta-catenin and collagen production in vitro⁶. A 2015 Journal of Experimental Medicine study reported that disrupting the CXXC5-Dvl interaction accelerated skin repair in mouse models.

The foundational 2017 mouse study, reported in the Journal of Investigative Dermatology (137(11):2260–2269), demonstrated visible hair regrowth and de novo follicle neogenesis in mice³. Lee 2017 reported that PTD-DBM disrupted CXXC5-Dishevelled binding, restored Wnt/beta-catenin signaling, and stimulated hair regrowth and wound-induced hair neogenesis in mouse models. One profile reports that topical PTD-DBM alone produced visible hair regrowth in C57BL/6 mice at levels comparable to minoxidil, and another reports that topical PTD-DBM applied to shaved mouse skin induced new follicles from epidermal and dermal progenitor cells, histologically confirmed with proper dermal papilla organization, inner and outer root sheaths, and hair fiber production³. In cultured human dermal papilla cells, one source reports PTD-DBM restored alkaline phosphatase activity and increased expression of versican, beta-catenin, and LEF-1.

Animal studies report that combining PTD-DBM with valproic acid (a GSK-3beta inhibitor and Wnt activator) produced significantly greater hair follicle neogenesis than either agent alone, with new follicle counts exceeding vehicle control by over 2-fold^3,6. One profile cautions that because the amplified effect was seen with the combination, standalone topical use may be substantially less effective than the published combination protocol. Additional mouse work reports that PTD-DBM restored hair loss caused by PGD, overcame PGD suppression of neogenic hair growth, and alleviated DHT-induced hair loss (PubMed 36831222⁵). On the wound-healing side, the 2015 study reported that co-treatment of skin wounds with PTD-DBM and valproic acid synergistically accelerated cutaneous wound healing in mice⁶; a study (PubMed 36854308) reported HA-PG patches loaded with PTD-DBM and valproic acid inhibited scar formation, suppressed alpha-smooth muscle actin, induced stem-cell markers CD105 and Nestin, and induced collagen III⁴; and one vendor profile cites an Adv Healthc Mater 2023 report that PTD-DBM delivered via adhesive hydrogel promoted regenerative, scar-free wound healing.

Human evidence and target relevance

One profile cites a 2023 PMC study confirming CXXC5 overexpression in androgenetic alopecia scalp biopsies, with other sources noting CXXC5 is increased in bald scalps, supporting target relevance in human disease³. Beyond target relevance, human efficacy claims conflict. A tier-1 PubMed review states that PTD-DBM activates Wnt/beta-catenin by interfering with CXXC5 and shows clinical efficacy as a peptide therapeutic for hair follicle growth, with potential as a more effective option than finasteride and minoxidil¹. One article states PTD-DBM is the only injectable peptide with a published human study directly showing increased hair follicle count, but describes that study (Choi et al., 2017, n=34) as small and unregistered, and a tier-4 vendor profile claims a Phase 1/2 trial (n=40, 24 weeks) demonstrated a +28.4% hair count increase versus baseline with no serious adverse events(vendor claim). Against these, multiple sources state that as of 2026 no completed peer-reviewed human clinical trials or RCTs of PTD-DBM have been published, all direct efficacy data coming from mouse models and in vitro dermal papilla studies. Separately, a tier-2 review notes that a phase 2A trial of PP405 — a different hair-follicle-stem-cell-activating peptide, not PTD-DBM — demonstrated statistically significant hair regrowth in eight weeks among 78 patients².

Positioning

One vendor guide notes PTD-DBM is described as unique in targeting Wnt/beta-catenin via CXXC5 inhibition, a mechanism distinct from minoxidil (blood flow), finasteride (DHT blocking), and GHK-Cu (gene-expression modulation), noting minoxidil produces roughly 40% moderate responders(vendor claim).

Regulatory and safety status

Multiple sources state that PTD-DBM is not FDA- or EMA-approved, has no IND filing as of April 2026, is not legally marketed for human use in the United States, and is sold for research and cosmetic use only. One dosage profile states that lyophilized peptides are investigational chemical compounds not approved for human consumption, diagnosis, or therapy(vendor claim).

Adverse events reported

Direct human safety data are essentially absent. The only adverse-event claim among the sources is from a tier-4 vendor profile, which reports "no serious adverse events" in a claimed Phase 1/2 trial (n=40, 24 weeks) — a claim that conflicts with the consensus that no completed peer-reviewed human trials have been published. No systematic human tolerability or long-term safety profile is established in the provided sources.

Quality and injectable-use caution

One article states that endotoxin testing (LAL assay, below 1 EU/mg) on a certificate of analysis is essential for any injectable peptide, and that most consumer-market peptide sellers do not provide endotoxin testing.

Combination caution

Much of the strongest preclinical hair-neogenesis and wound-healing data used PTD-DBM combined with valproic acid; one source cautions that standalone topical use may be substantially less effective than the published combination protocol. One vendor profile states that PTD-DBM combined with valproic acid, used in hair-regeneration protocols, requires careful medical supervision(vendor claim). Note that valproic acid is separately described as a drug used for bipolar disorder that inhibits GSK3beta³.

Evidence limitation

Efficacy and safety inferences rest overwhelmingly on mouse and in vitro data; human pharmacokinetics are not established, and dosing figures are extrapolated or vendor-derived rather than clinically validated.

Dosing

No dose has been established for this compound. No regulatory label exists for PTD-DBM — it is not FDA- or EMA-approved and has no IND filing as of April 2026 — so the figures below are what sources report, not guidance. Direct efficacy evidence is preclinical, and dosing figures are extrapolated or vendor-derived.

Topical figures sources report

• One dosage profile suggests a typical topical dose of 0.5–1 mg/mL applied to the scalp (~250–1000 mcg per application), commonly once daily(vendor claim).
• Rodent studies are described by vendor material as typically using 1–5 mg/mL dissolved in DMSO/PBS⁷.
• Community and vendor sources report PTD-DBM is often applied topically or via microneedling for androgenetic alopecia and hair thinning, with 1–2 microneedling sessions per week said to enhance results(vendor claim).
• One vendor source recommends applying once daily, preferably in the evening, while another suggests morning timing, with 3–6 months typically described before visible improvements(vendor claim).
• One vendor profile describes a valproic-acid combination over a 3–6 month course, requiring careful medical supervision(vendor claim).

Reconstitution

These are container calculations reported by vendor/dosage sources, not dose recommendations:

• Vendor dosing material describes reconstitution via a topical vehicle such as DMSO or a gel base⁷.
• One dosage guide lists a 5 mg vial reconstituted with 2.5 mL bacteriostatic water to a 2 mg/mL concentration, giving 20 mcg (0.0200 mg) per U-100 insulin-syringe unit(vendor claim).
• One profile describes a 5 mg vial reconstituted with 2 mL bacteriostatic water yielding 2,500 mcg/mL and about 20 doses per vial.

Storage

Vendor storage guidance advises that PTD-DBM has limited stability and should be prepared fresh, stored refrigerated at 2–8°C or frozen at −20°C, with a reconstituted-solution shelf life of about 2–4 weeks (one source says 30 days)⁷.

Quality note

One article states that for any injectable peptide, endotoxin testing (LAL assay, below 1 EU/mg) on a certificate of analysis is essential, and that most consumer-market sellers do not provide it.

1. 1.
   Revolutionary Approaches to Hair Regrowth: Follicle Neogenesis, Wnt/ß-Catenin Signaling, and Emerging Therapies.(opens in a new tab)

   Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2025
2. 2.
   Overview of Short Peptides for Hair Loss - PMC(opens in a new tab)

   Tier 2Web · pmc.ncbi.nlm.nih.gov
3. 3.
   PTD-DBM - Wikipedia(opens in a new tab)

   Tier 2Web · en.wikipedia.org
4. 4.
   Adhesive Hydrogel Patch-Mediated Combination Drug Therapy Induces Regenerative Wound Healing through Reconstruction of Regenerative Microenvironment.(opens in a new tab)

   Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
5. 5.
   CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD.(opens in a new tab)

   Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
6. 6.
   The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing.(opens in a new tab)

   Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2015
7. 7.
   PTD-DBM: Research Guide — Dosing, Half-Life & Protocols | Lumen Peppers(opens in a new tab)

   Tier 3Web · lumenpeppers.com · 2026